Clinical trials: Plasma Cell Disorder, open to volunteers
Relapsed/Refractory Multiple Myeloma (RRMM)
IASO206 in Patients With Relapsed/Refractory Multiple Myeloma
This study is an open-label, single-arm early exploratory clinical study, aiming to evaluate the safety, tolerability and preliminary efficacy of IASO206 Injection(In Vivo CAR-T) in Patients with Relapsed/Refractory Multiple…
- Trial name
- NCT07322159
- Testing
- IASO206 injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region "Living With a Myeloma in West-Occitanie"
Actually very few real life data are available for patients with multiple myeloma (MM), whereas they're playing a more and more important role in health care decisions.
- Trial name
- VAMOS (NCT04888039)
- Testing
- quality of life questionnaires (EORTC QLQ-C30 ; EORTC QLQMY20 ; EQ-5D-5L ; Cohen's stress scale)
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- University Hospital, Toulouse
Relapsed or Refractory Multiple Myeloma
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple Myeloma(RRMM).
- Trial name
- NCT06375044
- Testing
- SIM0500
- Where
- 16 sites in United States, China
- Volunteers
- 130 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Multiple Myeloma
Isa-VRD in TIE HRMM
This is a multicenter, prospective, randomized controlled trial designed to compare the quadruplet regimen of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRD) with the standard triplet regimen (VRD) in newly…
- Trial name
- NCT07334535
- Testing
- Isatuximab, bortezomib, lenalidomide, dexamethason, Bortezomib, Lenalidomide, Dexamethasone
- Where
- China
- Volunteers
- 117 people
- Sponsor
- Peking Union Medical College Hospital
Multiple Myeloma, Monocytes
Quantitative and Qualitative Monocytes Analysis and Their Impact on CART Cells Reponse in Multiple Myeloma
Tumoral micro-environment in malignant haematological diseases, notably in multiple myeloma, is active on plasma cells survival and proliferation.
- Conditions
- Multiple Myeloma, Monocytes, CART Cells
- Trial name
- MONOMM (NCT07180992)
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Multiple Myeloma (MM)
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
The purpose of this study is to compare the pharmacokinetic (PK) similarity, safety, tolerability, immunogenicity, and efficacy of HLX15-SC versus US-DARZALEX FASPRO® following single and multiple subcutaneous (SC) injections in…
- Trial name
- NCT07477587
- Testing
- HLX15-SC-Rd, US-DARZALEX FASPRO®-Rd
- Where
- 84 sites in United States, Australia and 3 more
- Volunteers
- 258 people
- Sponsor
- Shanghai Henlius Biotech
Myeloma Multiple
A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma
The BELAMI trial is an open label, multicenter, phase 2 study for patients with MM who relapsed following BCMA-directed CAR-T cells or bispecific antibodies with a Phase Ib Safety run-in.
- Trial name
- BELAMI (NCT07612787)
- Testing
- CAR-T cells, BCMA bispecific
- Where
- 30 sites in France
- Volunteers
- 44 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Relapsed or Refractory Multiple Myeloma
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
The purpose of the study is to compare the efficacy of QLS32105 (SC) in combination with Pomalidomide, and QLS32105 (SC) in combination with QL2109 or Daratumumab, and QLS32105 (SC) in combination with QL2109 or Daratumumab and…
- Trial name
- NCT07018050
- Testing
- QLS32015, Pomalidomide, Dexamethasone
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
AL Amyloidosis
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
This study will evaluate the safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis.
- Trial name
- NCT06569147
- Testing
- Elranatamab
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Dana-Farber Cancer Institute
Leukemia, Lymphoma
RAT-HEMATO : Return to Work After Malignant Hemopathy
Return to work (RTW) of patients after cancer treatment has been a topic of growing interest for the past two decades. Advances in cancer care have led to better patient survival, with some cancers considered as chronic or even…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- RAT-HEMATO (NCT06262789)
- Testing
- "Return-to-work after cancer" consultation
- Where
- 10 sites in France
- Volunteers
- 264 people
- Sponsor
- University Hospital, Angers